PCSA
Processa Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.73
+2.37%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.74
From 52W high−82.22%
Volume19676.00
Market cap$4.83M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.74
From 52W high
−82.22%
Volume
19676.00
Market cap
$4.83M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
P/E (TTM)
—
RSI (14)
49.5
MomentumView details →
1D Return
+2.37%
YTD Return
−39.58%
SummaryUpdated Jun 1, 2026
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) is a clinical-stage biopharmaceutical company founded in 2011 and based in Hanover, Maryland. The company went public in March 2014 and focuses on developing innovative drug products to address unmet medical needs, particularly in oncology and gastrointestinal disorders. Processa operates as a development-stage company with no current revenue, relying on clinical trials to advance its pipeline of potential therapeutic treatments through regulatory approval processes.
Similar companies
Latest newsMore news →